From: Assessing service availability and readiness to manage cervical cancer in Bangladesh
Tracer Items | Total | Tertiary & Specialized Hospital | District Hospital | MCWC | UHC | NGO/Private Hospital |
---|---|---|---|---|---|---|
Staff and guideline [n (index score in %)] | ||||||
 Oncologists | 31 (9.6) | 7 (100.0) | 9 (15.5) | 0 (0.0) | 1 (0.8) | 14 (18.9) |
 Palliative care specialist | 4 (1.2) | 3 (42.9) | 1 (1.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
 Trained Nurse | 9 (2.8) | 5 (71.4) | 2 (3.4) | 0 (0.0) | 1 (0.8) | 1 (1.4) |
 Guideline a | 41 (12.7) | 7 (100.0) | 10 (17.2) | 3 (5.0) | 11 (8.9) | 10 (13.5) |
 Training a | 32 (9.9) | 7 (100.0) | 6 (10.3) | 3 (5.0) | 13 (10.5) | 3 (4.1) |
Equipment [n (index score in %)] | ||||||
 Beds available for cancer patients | 26 (8.0) | 7 (100.0) | 7 (12.1) | 0 (0.0) | 8 (6.5) | 4 (5.4) |
 Speculum a | 152 (47.1) | 7 (100.0) | 36 (62.1) | 28 (46.7) | 57 (46.0) | 24 (32.4) |
Diagnostic facility [n (index score in %)] | ||||||
 Acetic Acid a | 136 (42.1) | 6 (85.7) | 36 (62.1) | 27 (45.0) | 53 (42.7) | 14 (18.9) |
 Sputum for Cytology | 80 (24.8) | 7 (100.0) | 20 (34.5) | 1 (1.7) | 27 (21.8) | 25 (33.8) |
 Stool occult blood test (OBT) | 75 (23.2) | 7 (100.0) | 14 (24.1) | 1 (1.7) | 21 (16.9) | 32 (43.2) |
 Cancer antigen 15.3 (CA 15.3) | 24 (7.4) | 5 (71.4) | 3 (5.2) | 1 (1.7) | 1 (0.8) | 14 (18.9) |
 Cancer antigen 19.9 (CA 19.9) | 23 (7.1) | 5 (71.4) | 3 (5.2) | 1 (1.7) | 1 (0.8) | 13 (17.6) |
 Carcinoembryonic antigen (CEA) | 23 (7.1) | 5 (71.4) | 3 (5.2) | 1 (1.7) | 1 (0.8) | 13 (17.6) |
 Cancer antigen 125 (CA125) | 23 (7.1) | 5 (71.4) | 3 (5.2) | 1 (1.7) | 1 (0.8) | 13 (17.6) |
 Alpha Keto Protein | 25 (7.7) | 5 (71.4) | 3 (5.2) | 1 (1.7) | 2 (1.6) | 14 (18.9) |
 Endoscopy of upper gastrointestinal tract | 43 (13.3) | 7 (100.0) | 10 (17.2) | 0 (0.0) | 4 (3.2) | 22 (29.7) |
 Colonoscopy | 35 (10.8) | 7 (100.0) | 8 (13.8) | 0 (0.0) | 2 (1.6) | 18 (24.3) |
 Pituitary tumor-transforming gene 1-binding factor (PBF) | 55 (17.0) | 7 (100.0) | 14 (24.1) | 0 (0.0) | 7 (5.6) | 27 (36.5) |
 Bone Marrow Study | 21 (6.5) | 7 (100.0) | 2 (3.4) | 0 (0.0) | 1 (0.8) | 11 (14.9) |
 Biopsy for Histopathology | 35 (10.8) | 7 (100.0) | 9 (15.5) | 0 (0.0) | 1 (0.8) | 18 (24.3) |
 Fine Needle Aspiration Cytology (FNAC) | 35 (10.8) | 6 (85.7) | 8 (13.8) | 0 (0.0) | 1 (0.8) | 20 (27.0) |
Medicines [n (index score in %)] | ||||||
 Hydrocortisone | 150 (46.4) | 7 (100.0) | 33 (56.9) | 18 (30.0) | 57 (46.0) | 35 (47.3) |
 Pheniramine | 61 (18.9) | 5 (71.4) | 11 (19.0) | 10 (16.7) | 17 (13.7) | 18 (24.3) |
 Ondanseron | 84 (26.0) | 6 (85.7) | 20 (34.5) | 6 (10.0) | 22 (17.7) | 30 (40.5) |
 Haloperidol | 40 (12.4) | 6 (85.7) | 11 (19.0) | 3 (5.0) | 4 (3.2) | 16 (21.6) |
 Morphin injection | 28 (8.7) | 6 (85.7) | 8 (13.8) | 2 (3.3) | 4 (3.2) | 8 (10.8) |
 Morphin tablet | 23 (7.1) | 4 (57.1) | 7 (12.1) | 1 (1.7) | 4 (3.2) | 7 (9.5) |
 Lorazepam | 47 (14.6) | 5 (71.4) | 12 (20.7) | 4 (6.7) | 10 (8.1) | 16 (21.6) |
 Hyoscine butylebromide | 65 (20.1) | 7 (100.0) | 13 (22.4) | 6 (10.0) | 21 (16.9) | 18 (24.3) |
 Broad Spectrum Antibiotics | 151 (46.7) | 7 (100.0) | 37 (63.8) | 20 (33.3) | 55 (44.4) | 32 (43.2) |
 Chemotherapeutic drugs | 17 (5.3) | 5 (71.4) | 2 (3.4) | 1 (1.7) | 3 (2.4) | 6 (8.1) |